$GRCE

2023 Q1 Form 10-Q Financial Statement

#000095017023002695 Filed on February 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue $0.00
YoY Change -100.0%
Gross Profit $0.00
YoY Change -100.0%
Gross Profit Margin
Selling, General & Admin $2.520M $1.795M $2.046M
YoY Change 21.33% -12.27% 53.72%
% of Gross Profit
Research & Development $370.0K $2.450M $2.179M
YoY Change -56.37% 12.44% 221.39%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $4.160M $4.245M $4.225M
YoY Change -5.52% 0.47% 110.3%
Operating Profit -$4.245M -$4.474M
YoY Change -5.12% 127.8%
Interest Expense $190.0K $79.00K $696.0K
YoY Change -164.19% -88.65% -155.41%
% of Operating Profit
Other Income/Expense, Net -$80.00K $82.00K $696.0K
YoY Change -154.42% -88.22% -155.41%
Pretax Income -$37.96M -$4.163M -$3.778M
YoY Change 733.92% 10.19% 17.33%
Income Tax -$8.870M -$274.0K $0.00
% Of Pretax Income
Net Earnings -$29.09M -$3.889M -$3.778M
YoY Change 645.13% 2.94% 17.33%
Net Earnings / Revenue
Basic Earnings Per Share -$0.09 -$0.09
Diluted Earnings Per Share -$3.88 -$0.09 -$85.30K
COMMON SHARES
Basic Shares Outstanding 44.61M 44.61M 44.29M
Diluted Shares Outstanding 44.61M 44.29M

Balance Sheet

Concept 2023 Q1 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.89M $31.26M $46.33M
YoY Change -36.12% -32.53% 65.93%
Cash & Equivalents $27.88M $26.24M $33.01M
Short-Term Investments $15.00K $5.015M $13.31M
Other Short-Term Assets $600.0K $1.394M $2.434M
YoY Change -54.61% -42.73% 47.78%
Inventory
Prepaid Expenses $598.0K $1.042M $1.847M
Receivables $802.0K $778.0K $238.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $29.29M $33.43M $49.00M
YoY Change -35.32% -31.78% 62.25%
LONG-TERM ASSETS
Property, Plant & Equipment $12.20M $599.0K $22.00K
YoY Change -41.61% 2622.73% -79.05%
Goodwill $8.138M $12.96M
YoY Change -37.23%
Intangibles $41.13M $69.81M $65.21M
YoY Change -41.09% 7.06%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $49.83M $83.37M $65.23M
YoY Change -40.2% 27.81% 62023.81%
TOTAL ASSETS
Total Short-Term Assets $29.29M $33.43M $49.00M
Total Long-Term Assets $49.83M $83.37M $65.23M
Total Assets $79.12M $116.8M $114.2M
YoY Change -38.48% 2.25% 276.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $3.360M $2.843M
YoY Change -33.46% 18.19% 35.38%
Accrued Expenses $946.0K $73.00K $22.00K
YoY Change 219.59% 231.82% -79.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.411M $3.433M $2.897M
YoY Change 4.63% 18.5% 28.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $400.0K $430.0K $268.0K
YoY Change 99.0% 60.45% -88.55%
Total Long-Term Liabilities $400.0K $430.0K $268.0K
YoY Change 99.0% 60.45% -88.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.411M $3.433M $2.897M
Total Long-Term Liabilities $400.0K $430.0K $268.0K
Total Liabilities $11.17M $20.08M $3.165M
YoY Change -45.12% 534.47% -31.02%
SHAREHOLDERS EQUITY
Retained Earnings -$198.3M -$169.2M -$151.9M
YoY Change 27.23% 11.35% 8.24%
Common Stock $258.3M $258.3M $258.0M
YoY Change 0.12% 0.12% 59.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $67.96M $96.72M $111.1M
YoY Change
Total Liabilities & Shareholders Equity $79.12M $116.8M $114.2M
YoY Change -38.48% 2.25% 276.95%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$29.09M -$3.889M -$3.778M
YoY Change 645.13% 2.94% 17.33%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change
Cash From Operating Activities -$3.320M -$3.722M -$4.584M
YoY Change 5.56% -18.8% 8.78%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $5.000M -$5.001M $557.0K
YoY Change 45354.55% -997.85% -140.6%
Cash From Investing Activities $4.990M -$5.001M $557.0K
YoY Change 45263.64% -997.85% -140.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -3.320M -3.722M -4.584M
Cash From Investing Activities 4.990M -5.001M 557.0K
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash 1.670M -8.723M -3.916M
YoY Change -153.29% 122.75% -126.12%
FREE CASH FLOW
Cash From Operating Activities -$3.320M -$3.722M -$4.584M
Capital Expenditures $10.00K $0.00 $0.00
Free Cash Flow -$3.330M -$3.722M -$4.584M
YoY Change 5.88% -18.8% 8.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001444192
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Other Income
OtherIncome
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Other Income
OtherIncome
CY2022Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35776
dei Entity Registrant Name
EntityRegistrantName
Acasti Pharma Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1359336
dei Entity Address Address Line1
EntityAddressAddressLine1
3009 boul. de la Concorde East, Suite 102
dei Entity Address City Or Town
EntityAddressCityOrTown
Laval
dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H7E 2B5
dei City Area Code
CityAreaCode
450
dei Local Phone Number
LocalPhoneNumber
686-4555
dei Security12b Title
Security12bTitle
Common Shares, no par value per share
dei Trading Symbol
TradingSymbol
ACST
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44612831
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26241000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30339000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
5015000
CY2022Q1 us-gaap Short Term Investments
ShortTermInvestments
13322000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
778000
CY2022Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
548000
CY2022Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
352000
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
352000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1042000
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
720000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
33428000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
45281000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
487000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
263000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
315000
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
112000
CY2022Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
250000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69810000
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
69810000
CY2022Q4 us-gaap Goodwill
Goodwill
12964000
CY2022Q1 us-gaap Goodwill
Goodwill
12964000
CY2022Q4 us-gaap Assets
Assets
116801000
CY2022Q1 us-gaap Assets
Assets
128620000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3360000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3156000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
73000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
104000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3433000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3260000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
10000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
430000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
191000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16218000
CY2022Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16889000
CY2022Q4 us-gaap Liabilities
Liabilities
20081000
CY2022Q1 us-gaap Liabilities
Liabilities
20350000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
258294000
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
257990000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
13643000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12154000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6038000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6037000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-169179000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155837000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
96720000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116801000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128620000
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2450000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2179000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8332000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3233000
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1589000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1808000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5187000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7441000
CY2022Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
206000
CY2021Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
238000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
563000
CY2021Q4 acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4245000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4474000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14082000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11186000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
82000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
696000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5271000
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4163000
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3778000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14013000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5915000
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-274000
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-671000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3889000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3778000
us-gaap Net Income Loss
NetIncomeLoss
-13342000
us-gaap Net Income Loss
NetIncomeLoss
-5915000
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44612831
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44612831
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44288183
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44288183
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44497907
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44497907
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25785579
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25785579
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108270000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4524000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
195000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
464000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
104403000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4929000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
109000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
582000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
100164000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-3889000
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
443000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
96720000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
55660000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3118000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
762000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
153000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
53457000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
981000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1149000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
114000
CY2021Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
60801000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
114204000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-3778000
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
187000
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
454000
CY2021Q4 us-gaap Exchange Fees
ExchangeFees
5000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111062000
us-gaap Net Income Loss
NetIncomeLoss
-13342000
us-gaap Net Income Loss
NetIncomeLoss
-5915000
us-gaap Depreciation
Depreciation
116000
us-gaap Depreciation
Depreciation
0
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
0
acst Impairment Of Other Assets And Prepaids
ImpairmentOfOtherAssetsAndPrepaids
249000
us-gaap Share Based Compensation
ShareBasedCompensation
1489000
us-gaap Share Based Compensation
ShareBasedCompensation
721000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4908000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-671000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
28000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
418000
acst Write Off Of Equipment
WriteOffOfEquipment
31000
acst Write Off Of Equipment
WriteOffOfEquipment
0
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
172000
acst Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
3818000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12587000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14089000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
9000
us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5015000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
34852000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
13185000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
31319000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
8161000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3533000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
304000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-110000
acst Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
-176000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
134000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-131000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4098000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17929000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30339000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50942000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26241000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
33013000
CY2022Q4 us-gaap Cash
Cash
26241000
CY2021Q4 us-gaap Cash
Cash
33013000
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-left:1.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1. Nature of operation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part 1A of the Companies Act (Québec)). The Corporation is domiciled in Canada and its registered office is located at 3009 boul. de la Concorde East, Suite 102, Laval, Québec, Canada H7E 2B5.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2021, the Corporation completed the acquisition via a share-for-share merger of Grace Therapeutics, Inc. (“Grace”), a privately held emerging biopharmaceutical company focused on developing innovative drug delivery technologies for the treatment of rare and orphan diseases. The post-merger Corporation is focused on building a late-stage specialty pharmaceutical company specializing in rare and orphan diseases and developing and commercializing products that improve clinical outcomes using our novel drug delivery technologies. The Corporation seeks to apply new proprietary formulations to existing pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients chosen by the Corporation for further development may be already approved in the target indication or could be repurposed for use in new indications.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation has incurred operating losses and negative cash flows from operations in each year since its inception. The Corporation expects to incur significant expenses and continued operating losses for the foreseeable future. The Corporation expects its expenses will increase substantially in connection with its ongoing activities, particularly as it advances clinical development for the first three drug candidates in the Corporation’s pipeline; continues to engage contract manufacturing organizations (“CMO's”) to manufacture its clinical study materials and to ultimately develop large-scale manufacturing capabilities in preparation for commercial launch; seeks regulatory approval for its drug candidates; and adds personnel to support its drug product development and future drug product launch and commercialization.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation does not expect to generate revenue from product sales unless and until it successfully completes drug development and obtains regulatory approval, which the Corporation expects will take several years and is subject to significant uncertainty. To date, the Corporation has financed its operations primarily through public offerings and private placements of its common shares, warrants and convertible debt and the proceeds from research tax credits. Until such time that the Corporation can generate significant revenue from drug product sales, if ever, it will require additional financing, which is expected to be sourced from a combination of public or private equity or debt financing or other non-dilutive sources, which may include fees, milestone payments and royalties from collaborations with third parties. Arrangements with collaborators or others may require the Corporation to relinquish certain rights related to its technologies or drug product candidates. Adequate additional financing may not be available to the Corporation on acceptable terms, or at all. The Corporation’s inability to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategy.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management expects the Corporation to have sufficient cash resources to satisfy its objectives into the second quarter of calendar 2024, which is 13 to 16 months from the issuance date of these Financial Statements. The Corporation will require additional capital to fund our daily operating needs beyond that time. The Corporation plans to raise additional capital prior to that time in order to maintain adequate liquidity. Negative results from studies, if any, and depressed prices of the Corporation’s stock could impact the Corporation’s ability to raise additional financing. Raising additional equity capital is subject to market conditions not within the Corporation’s control. If the Corporation does not raise additional funds in this time period, the Corporation may not be able to realize our assets and discharge our liabilities in the normal course of business.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Corporation remains subject to risks similar to other development stage companies in the biopharmaceutical industry, including compliance with government regulations, protection of proprietary technology, dependence on third party contractors and consultants and potential product liability, among others.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reverse stock split</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On August 26, 2021, the shareholders of the Corporation approved a resolution to undertake a reverse split of the common shares within a range of 1-6 to 1-8 with such specific ratio to be approved by the Acasti Board. All references in these financial statements to number of common shares, warrants and options, price per share and weighted average number of shares outstanding prior to the reverse split have been adjusted to reflect the approved reverse split of 1-</span><span style="font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which was made effective on August 31, 2021, on a retroactive basis as of the earliest period presented.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates are based on management’s best knowledge of current events and actions that management may undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="margin-left:1.147%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Estimates and assumptions include the measurement of derivative warrant liabilities (note 7), stock-based compensation (note 10), assets held for sale (note 6), supply agreement (note 12), valuation of intangibles (note 4) and goodwill. Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and development expenditures at each reporting date, including whether contingencies should be accrued for, as well as in determining which research and development expenses qualify for investment tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q4 us-gaap Goodwill
Goodwill
12964000
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
5015000
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
13322000
CY2022Q2 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Cost
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCost
696000
CY2022Q2 acst Disposal Group Including Discontinued Operation Property Plant And Equipment Accumulated Depreciation
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentAccumulatedDepreciation
446000
CY2022Q2 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
-250000
CY2022Q2 us-gaap Depreciation Expense On Reclassified Assets
DepreciationExpenseOnReclassifiedAssets
167000
CY2020Q2 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2020Q2 acst Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
0.030
CY2021Q4 acst Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
75000000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
32390
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
161000
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
15000
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-172000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-75000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
172000
CY2021Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-828000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4908000
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
64000
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
40000
us-gaap Investment Income Interest
InvestmentIncomeInterest
59000
us-gaap Investment Income Interest
InvestmentIncomeInterest
191000
CY2022Q4 us-gaap Other Income
OtherIncome
3000
us-gaap Other Income
OtherIncome
75000
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
82000
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
696000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5271000
acst Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
1.10
acst Shares Price
SharesPrice
1.10
acst Share Based Compensation Arrangement By Share Based Payment Award Option Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionNonvestedWeightedAverageGrantDateFairValue
0.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.1756
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0327
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y8M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-268000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
292000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-382000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1507000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
478000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2603000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
-172000
acst Increase Decrease In Non Cash Working Capital
IncreaseDecreaseInNonCashWorkingCapital
-3818000

Files In Submission

Name View Source Status
acst-20221231_pre.xml Edgar Link unprocessable
acst-20221231_cal.xml Edgar Link unprocessable
0000950170-23-002695-index-headers.html Edgar Link pending
0000950170-23-002695-index.html Edgar Link pending
0000950170-23-002695.txt Edgar Link pending
0000950170-23-002695-xbrl.zip Edgar Link pending
acst-20221231.htm Edgar Link pending
acst-20221231.xsd Edgar Link pending
acst-ex31_1.htm Edgar Link pending
acst-ex31_2.htm Edgar Link pending
acst-ex32_1.htm Edgar Link pending
acst-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img179522247_0.jpg Edgar Link pending
img179522247_1.jpg Edgar Link pending
img179522247_10.jpg Edgar Link pending
img179522247_11.jpg Edgar Link pending
img179522247_12.jpg Edgar Link pending
img179522247_2.jpg Edgar Link pending
img179522247_3.jpg Edgar Link pending
img179522247_4.jpg Edgar Link pending
acst-20221231_def.xml Edgar Link unprocessable
acst-20221231_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
acst-20221231_htm.xml Edgar Link completed
img179522247_5.jpg Edgar Link pending
img179522247_6.jpg Edgar Link pending
img179522247_7.jpg Edgar Link pending
img179522247_8.jpg Edgar Link pending
img179522247_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending